Researchers at Penn Medicine have discovered a new, more effective method of preventing the body’s own proteins from treating nanomedicines like foreign invaders, by covering the nanoparticles with a coating to suppress the immune response that dampens the therapy’s effectiveness.
- Phytochemical in a Himalayan plant inhibits the COVID-19 virus
admin Fri, 01/21/2022 - 15:39
Researchers from the Indian Institute of Technology, Mandi, and The International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, have identified Phytochemicals in the petals of a Himalayan plant that could potentially be used to treat COVID-19 infections.
The findings of the research team have been recently published in the journal Biomolecular Structure and Dynamics.
- Oral penicillin, not injectable, advised for people with high-risk rheumatic heart disease
admin Wed, 01/19/2022 - 16:04
A growing body of evidence indicates that some people thought to have an allergic response to injectable penicillin, the standard treatment for rheumatic heart disease, may instead be experiencing a cardiac reaction to the medicine, according to a new American Heart Association presidential advisory published today in Journal of the American Heart Association.
- Health Canada authorizes PAXLOVIDTM for patients with mild to moderate COVID-19 at high risk of developing serious disease
admin Wed, 01/19/2022 - 15:56
Health Canada has authorized the combination of two antiviral drugs, nirmatrelvir and ritonavir (brand name PAXLOVIDTM), to treat adults with mild to moderate COVID-19 who are at high risk of progressing to serious disease, including hospitalization or death. The active ingredient nirmatrelvir in PAXLOVIDTM works by stopping the virus from replicating.
- Pfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant
admin Wed, 01/19/2022 - 15:51
Pfizer Inc shared results from multiple studies demonstrating that the in vitro efficacy of nirmatrelvir, the active main protease (Mpro) inhibitor of PAXLOVID (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), is maintained against the SARS-CoV-2 variant Omicron. Taken together, these in vitro studies suggest that PAXLOVID has the potential to maintain plasma concentrations many-fold times higher than the amount required to prevent Omicron from replicating in cells.
- BiologyWorks k(now) COVID-19 Clinical Trial matches 99.1 percent accuracy to RT-PCR Tests
admin Wed, 01/19/2022 - 14:56
The independent clinical trial, conducted by Locus Medicus in Athens, Greece, prospectively tested 330 patients with symptomatic and asymptomatic cases of COVID-19. For the study, staff at the clinical laboratory collected two bilateral anterior nasal swabs from each patient. Immediately after collection, one swab was tested in the lab’s standard of care CE-Mark RT-PCR test and the other swab was tested by BiologyWorks k(now). Results from the BiologyWorks k(now) molecular test were 99.1% in overall percent agreement with the results of the RT-PCR lab tests.
- Nuclei-free Cells Prove Utility in Delivering Therapeutics to Diseased Tissues
admin Tue, 01/18/2022 - 16:56
Researchers at University of California San Diego School of Medicine and Moores Cancer Center at UC San Diego Health report successfully removing the nucleus out of a type of ubiquitous cell, known as enucleation, then using the genetically engineered cell as a unique cargo-carrier to deliver therapeutics precisely to diseased tissues.
- Nanotherapy offers new hope for the treatment of Type 1 diabetes
admin Tue, 01/18/2022 - 16:53
Individuals living with Type 1 diabetes must carefully follow prescribed insulin regimens every day, receiving injections of the hormone via syringe, insulin pump or some other device. And without viable long-term treatments, this course of treatment is a lifelong sentence.